(Z)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]-N-(3-phenylpropyl)prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]-N-(3-phenylpropyl)prop-2-enamide
• 化学式: C₂₅H₃₀N₂O₂
• 分子量: 390.5
• InChiKey: JANPYFTYAGTSIN-BKUYFWCQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Targeted multivalent macromolecules
  申请人：TARGESOME, INC.

  公开号：US20030129223A1

  公开（公告）日：2003-07-10

  Targeted therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and at least one targeting entity are provided, as well as methods for their preparation and use.

  靶向治疗剂，包括一个连接载体，与连接载体相关联的治疗实体，以及至少一个靶向实体，以及它们的制备和使用方法。
• MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
  申请人：Bracco Suisse S.A

  公开号：US20150374843A1

  公开（公告）日：2015-12-31

  The invention provides compositions and methods for therapeutic and diagnostic applications.

  本发明提供了用于治疗和诊断应用的组合物和方法。
• Method and compositions for inhibiting cell proliferative disorders
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem

  公开号：US20040242684A1

  公开（公告）日：2004-12-02

  The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.

  本发明涉及化合物及其用途，用于抑制受体酪氨酸激酶的活性。该发明最好用于治疗细胞增殖性疾病，如由HER2或EGFR过度活跃或不适当活跃引起的癌症。
• Methods and compositions for inhibiting cell proliferative disorders
  申请人：——

  公开号：US20020068687A1

  公开（公告）日：2002-06-06

  The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.

  本发明涉及化合物及其用途，用于抑制受体酪氨酸激酶的活性。该发明通常用于治疗细胞增殖性疾病，例如由HER2或EGFR过度活跃或不适当活跃引起的癌症。
• VEGF-A as an inhibitor of angiogenesis and methods of using same
  申请人：Ambati Jayakrishna

  公开号：US20060135423A1

  公开（公告）日：2006-06-22

  The invention relates to methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization associated with neovascular disease. Administration of vascular endothelial growth factor (VEGF)-A into the eye when macrophage infiltration is reduced inhibits ocular angiogenesis.

  本发明涉及治疗或预防与新生血管疾病相关的眼部血管生成和新生血管的方法和组合物。当巨噬细胞浸润减少时，向眼内注射血管内皮生长因子（VEGF）-A 可抑制眼部血管生成。